|
Overcoming Drug Development Challenges through Collaborative Partnerships
Kenneth I. Kaitin a keynote speaker at the marcus evans Evolution Summit 2015, on the challenge of clinical development and how companies are addressing it.
NEW YORK, N.Y., Aug 20, 2015 - (ACN Newswire) - "There is often misunderstanding and lack of appreciation by the public about the value of clinical trial participation. The industry should continue its efforts to educate people on the importance of clinical studies in supporting medical research and in the development of critical new medicines," advises Kenneth I. Kaitin, Professor and Director, Tufts Center for the Study of Drug Development, Tufts University School of Medicine.
Kaitin is a keynote speaker at the marcus evans Evolution Summit 2015 taking place in Las Vegas, Nevada, September 20-22.
- What are the complexities of bringing new drugs to market in the pharmaceutical industry today?
Our studies have shown that the current cost of bringing a single new drug to market, including the cost of failures, has skyrocketed to USD 2.6 billion, which represents a 145 percent increase from our previous study in 2003. High drug development costs are a significant obstacle for developers, with important public health consequences in terms of finding new treatments for unmet medical needs.
The most significant factor contributing to these high costs is not the considerable time it takes to develop a new drug, but rather the exceedingly low success rates of compounds entering clinical development. Our recent analysis indicates that overall clinical success rates have fallen from 22 percent in the early 2000s to less than 12 percent today. In some therapeutic areas, success rates are alarming low; for example, for neuropsychiatric drugs, less than five percent of drugs entering clinical trials are likely to reach the market.
The decrease in clinical success rates is due in part to increasing complexity built into clinical trials. There has been a steady rise in procedures done and protocol amendments filed during clinical development, which ultimately have made it harder to recruit and retain patients for clinical studies, prolonging study times and raising trial costs.
- What are companies doing to address these complexities?
Pharmaceutical companies, academic institutions, teaching hospitals, patient groups and government agencies are collaborating through consortia and integrated alliances to find better biomarkers and tools for determining what drugs are likely to succeed in clinical development.
Not long ago, many of the large legacy pharmaceutical companies took great pride in the fact that they alone could take a compound from the laboratory bench all the way to the marketplace. Now those same companies promote the fact that they actively partner with other organizations in the discovery and research phase, and that they have preferred-provider relationships with contract research organizations. Through these relationships, companies are able to contain research and development (R&D) costs, "de-risk" the development process, and increase the likelihood of success. The bottom line is that the era of the self-sufficient, fully-integrated pharmaceutical company is over. Companies are now engaging in partnerships and integrated alliances to reduce overall R&D spend and boost productivity.
- What would improve the quality of decision-making in clinical trials?
The clinical trial process has remained virtually unchanged for the past 50-plus years. Many companies have legacy systems in place that are not easily changed, made more difficult by the fact that product development times can last ten to 15 years. In response, some companies are developing new governance mechanisms for reviewing clinical protocols and the design of clinical studies to weed out inefficiencies in drug development programs. In some cases, companies have chosen to move the decision-making process outside the company, to get an objective efficiency assessment, rather than relying on individuals within the company, who may have a vested interest in keeping products alive.
The era of the self-sufficient, fully-integrated pharmaceutical company is over.
About the Evolution Summit 2015
The 9th Evolution Summit is the premium forum bringing clinical trial experts from leading drug development companies and solution providers together. The Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development. Taking place at Red Rock Resort & Spa, Las Vegas, Nevada, September 20-22, the Summit includes presentations on shaping the industry's future, viewing CROs as strategic business partners, analyzing the benefits of patient-centered drug development and patient recruitment and retention.
For more information please send an email to press@marcusevanscy.com or visit the event website at www.evolutionsummit.com/Kaitin_Interview
marcus evans group - life sciences / pharma sector portal - www.marcusevans.com/reviews/sciences
The Pharma Network - marcus evans Summits group delivers peer-to-peer information on strategic matters, professional trends and breakthrough innovations.
- LinkedIn: www.linkedin.com/groups?gid=3529112&trk=myg_ugrp_ovr
- YouTube: www.youtube.com/MarcusEvansPharma
- Twitter: www.twitter.com/meSummitsPharma
- SlideShare: www.slideshare.net/MarcusEvansPharma
Please note that the Summit is a closed business event and the number of participants strictly limited.
Contact:Luzdary Hammad
Press Manager, marcus evans, Summits Division
Tel: +357 22 849 385
Email: press@marcusevanscy.com
Source: marcus evans Summits
Sectors: Daily Finance, Daily News
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network. |
Latest Release
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
| 
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
| 
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
| 
Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST
| 
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST
| 
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST
| 
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST
|
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST
| 
Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST
| 
NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
Nov 19, 2024 15:30 JST
| 
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
Nov 19, 2024 09:02 JST
| 
CleverTap Recognized as a Strong Performer in Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 18, 2024 23:30 JST
| 
World's First Successful Trial of Quantum Tokens Created Using Quantum Technology
Nov 18, 2024 17:29 JST
|
Fujitsu and SAP Fioneer enter partnership to accelerate digital transformation in the insurance industry and deliver services that contribute to customers' sustainable business
Nov 18, 2024 12:31 JST
| 
Expanding Possibilities with the Liquid Hydrogen-Powered GR Corolla in the Season Final Round
Nov 18, 2024 09:25 JST
|
COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding
Nov 16, 2024 18:00 JST
|
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki
Nov 15, 2024 18:58 JST
|
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 17:33 JST
|
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 14:31 JST
| 
Resorttrust Group and Mitsubishi Corporation Launch Joint Study in Medical Tourism
Nov 15, 2024 12:32 JST
|
More Latest Release >>
|